Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens Boots Alliance Inc (NASDAQ:WBA) has reported first-quarter sales that beat expectations, sending its shares higher in Thursday premarket trading. The company, which is reported to be exploring a spinoff of its UK-based Boots drugstore chain, posted a 10% increase in sales to $36.7 billion for the three months to November 30, 2023, above the $34.9 billlion expected by analysts polled by Zacks Investment Research.

Walgreens shares rise on 1Q sales beat

Walgreens Boots Alliance quarterly losses narrowed and the drugstore chain announced plans to reduce its dividend by 48% to strengthen its balance sheet and cash position to invest in its businesses.

Walgreens Reduces Dividend To Free Up Cash, Invest In Stores And Specialty Pharmacy

Shares of Walgreens Boots Alliance Inc. WBA, -4.05% rallied 3.1% in premarket trading Thursday, after the drugstore chain and healthcare services company beat fiscal first-quarter earnings expectations, but said it was nearly halving its dividend to bolster its cash position. Net losses for the quarter to Nov. 30 narrowed to $67 million, or 8 cents a share, from $3.72 billion, or $4.31 a share, in the year-ago period.

Walgreens' stock jumps after earnings beat, dividend cut to boost cash position

Walgreens Boots Alliance on Thursday nearly halved its dividend payout as it attempts to conserve cash amid low consumer spending and intense competition, sending the U.S. pharmacy chain's shares down 11%.

Pharmacy chain Walgreens cuts dividend to save cash, shares slump

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the first quarter of fiscal 2024, which ended November 30, 2023. Chief Executive Officer Tim Wentworth said: "WBA delivered fiscal first quarter results in line with overall expectations, reflecting disciplined execution in a challenging consumer backdrop. We are evaluating all strategic options to drive sustainable long-term shareholder value, focusing on swift actions to right-.

Walgreens Boots Alliance Reports Fiscal 2024 First Quarter Results

The company announced a quarterly dividend of 25 cents per share, down from 48 cents a share.

Walgreens Meets Earnings Expectations, but Slashes Dividend

Dollar General

Verizon

As we kick off 2024 with optimism and fresh perspectives, it's time to look at the market and identify some prime value stocks poised for gains this year. With the economy steadily recovering, we can expect undervalued stocks to experience nice upside, as investor sentiment improves.

New Year, New Gains: The 3 Best Value Stocks to Buy in 2024

Walgreens Boots Alliance Inc (NASDAQ:WBA) is expected to report a decline in earnings when it reports back for the first quarter before the opening bell on Thursday. The company, which is reported to be exploring a spinoff of its UK-based Boots drugstore chain, will report 1Q revenues of $34.9 billion for the three months to end November, a year-over-year increase of 4.6%, according to analysts polled by Zacks Investment Research.

Walgreens likely to report lower 1Q earnings as it mulls Boots spinoff

The first big earnings report of the year is coming up on Thursday, Jan. 4, with Walgreens Boots Alliance Inc (NASDAQ:WBA) scheduled to announce its latest quarterly report before the open.

Walgreens Stock at a Crossroads Ahead of Earnings

Dow Inc

This segment operated 4,428 retail stores under the: Boots Benavides and Ahumada names in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile 550 optical practices, including 165 on a franchise basis.

The 2024 ‘Dogs of the Dow' Will Pay Huge Ultra-Yield Dividends

Walgreens' 7.2% dividend yield is high and may be unsustainable. The company has been increasing its payouts for decades.

Will Walgreens Boots Alliance's Dividend Growth Streak End in 2024?

Walgreens Boots Alliance WBA is in transformation. Just before announcing the year-end results in October, Tim Wentworth was appointed CEO of the company.

Walgreens Is In Transition – A New CEO – Hundreds Of Stores Shuttered

DISH Network

Moderna

Pfizer

The general stock market is concluding 2023 on a positive note, propelled by specific equities that have spearheaded an end-of-year rally. Significantly, these gains have enabled several stocks to recover from losses incurred in 2022.

Revealed: The most disappointing stocks of 2023

Chevron

Johnson & Johnson

Walgreens' turnaround plan could start paying dividends in 2024. Chevron's acquisitions will give it more fuel to grow its dividend in 2024 and beyond.

3 Beaten-Down Dow Jones Stocks That Dividend Investors Should Scoop Up in 2024

Conagra Brands

Lamb Weston Hlds

Constellation Brands

The economy's resilience in the face of the Fed's extraordinary tightening has been a pleasant surprise. That said, it makes sense for growth to moderate going forward to reflect the cumulative effect of monetary policy tightening.

How Will Earnings Estimates Evolve in 2024?

Get a deeper insight into the potential performance of Walgreens (WBA) for the quarter ended November 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Exploring Analyst Estimates for Walgreens (WBA) Q1 Earnings, Beyond Revenue and EPS

Albemarle

Bristol-Myers

Devon Energy

Estee Lauder

Enphase Energy

Eversource Energy

Etsy

Hormel Foods

Illumina

NextEra Energy

Paycom Software

Insulet

V.F.

The U.S. stock market staged a remarkable rally in 2023, but 173 stocks in the S&P 500 were still down for the year.

Here are the 20 worst-performing stocks among the S&P 500 in 2023

Apple

Amgen

Cisco Systems

Kinder Morgan

Merck

Microsoft

UnitedHealth Group

The Dow is an excellent starting place if you are looking for foundational holdings. However, some Dow stocks would be best for investors to avoid right now.

There Are Only 5 Dow Stocks I Wouldn't Buy in 2024

Alliance Resource Partners

Realty Income Corp

AT&T

Vale S.A.

Pursuing financial freedom often conjures images of dynamic markets, strategic maneuvers, and the allure of high-yield stocks. Imagine a tapestry woven with resilience, operational finesse, and the astuteness of market navigation.

Financial Freedom: 7 Exceptional High-Yield Stocks for Lasting Passive Gains

In the latest trading session, Walgreens Boots Alliance (WBA) closed at $26.60, marking a -0.15% move from the previous day.

Walgreens Boots Alliance (WBA) Stock Dips While Market Gains: Key Facts

Walgreens (WBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Walgreens Boots Alliance (WBA) Q1 Earnings Expected to Decline

Blue-chip name Walgreens Boots Alliance Inc (NASDAQ:WBA) is gearing up for its fiscal first-quarter earnings report, which is due out before the open on Thursday, Jan. 4.

Dow Component Prepares for First Earnings Call of 2024

The Dogs of the Dow theory assumes that this year's worst performers will be the best-performing stocks in the next. If not, they should provide solid rebounds due to their “lower” value, and many pay above-average dividends.

Are high-yield Dow Dogs a good buy for 2024?

Walgreens, Chevron, and Johnson & Johnson are the three worst performers on the Dow Jones Industrial Average in 2023. All three have clear reasons for their underperformance.

Is It Time to Buy the Dow Jones' 3 Worst Performing Stocks This Year?

Cincinnati Financial

Leggett & Platt

Medtronic

McCormick

ProShares S&P 500 Dividend Aristocrats ETF

J. M. Smucker

SPDR S&P 500 ETF Trust

Stanley Black & Decker

Target

T. Rowe Price Group

Exxon Mobil

The ProShares S&P 500 Dividend Aristocrats ETF continues its recent good run in December, through the 22nd, the ETF is up 3.91%. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term.

News for Walgreens Stock (WBA)